Madrigal Pharmaceuticals Inc (MDGL)
215.99
+5.91
(+2.81%)
USD |
NASDAQ |
May 02, 16:00
215.99
0.00 (0.00%)
After-Hours: 17:04
Madrigal Pharmaceuticals Research and Development Expense (Quarterly): 70.64M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 70.64M |
September 30, 2023 | 70.95M |
June 30, 2023 | 68.60M |
March 31, 2023 | 62.15M |
December 31, 2022 | 70.74M |
September 30, 2022 | 68.27M |
June 30, 2022 | 58.50M |
March 31, 2022 | 47.93M |
December 31, 2021 | 52.89M |
September 30, 2021 | 54.87M |
June 30, 2021 | 51.63M |
March 31, 2021 | 45.77M |
December 31, 2020 | 53.43M |
September 30, 2020 | 53.29M |
June 30, 2020 | 44.69M |
March 31, 2020 | 33.40M |
December 31, 2019 | 24.91M |
September 30, 2019 | 19.45M |
June 30, 2019 | 15.59M |
March 31, 2019 | 12.37M |
December 31, 2018 | 8.871M |
September 30, 2018 | 6.211M |
June 30, 2018 | 5.109M |
March 31, 2018 | 5.198M |
December 31, 2017 | 6.512M |
Date | Value |
---|---|
September 30, 2017 | 6.682M |
June 30, 2017 | 6.816M |
March 31, 2017 | 4.38M |
December 31, 2016 | 5.523M |
September 30, 2016 | 7.806M |
June 30, 2016 | 2.088M |
March 31, 2016 | 0.516M |
December 31, 2015 | 0.7732M |
September 30, 2015 | 0.6826M |
June 30, 2015 | 16.38M |
March 31, 2015 | 16.18M |
December 31, 2014 | 15.65M |
September 30, 2014 | 16.21M |
June 30, 2014 | 18.76M |
March 31, 2014 | 17.58M |
December 31, 2013 | 19.98M |
September 30, 2013 | 17.62M |
June 30, 2013 | 17.88M |
March 31, 2013 | 16.38M |
December 31, 2012 | 14.35M |
September 30, 2012 | 11.74M |
June 30, 2012 | 11.25M |
March 31, 2012 | 12.07M |
December 31, 2011 | 10.86M |
September 30, 2011 | 10.75M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
15.59M
Minimum
Jun 2019
70.95M
Maximum
Sep 2023
50.93M
Average
53.29M
Median
Sep 2020
Research and Development Expense (Quarterly) Benchmarks
Eli Lilly and Co | 2.523B |
Viking Therapeutics Inc | 24.10M |
Akero Therapeutics Inc | 53.39M |
89bio Inc | 33.59M |
Geron Corp | 32.91M |